San Diego, CA, United States of America

Evan W Rogers

This inventor holds 47 USPTO granted patents and 34 published patent applications, plus 5 CIPO patents and 14 EPO patents, primarily in Macrocyclic Compounds. Top assignees: Calcimedica, Inc., Turning Point Therapeutics, Inc., Aurora Operations, Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Evan W Rogers. Retrieved from https://idiyas.com/inventor/evan-w-rogers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 

% Patents Active = 89.4

 

 

Average Co-Inventor Count = 4.6

ph-index = 8

Forward Citations = 225(Granted Patents)


Location History:

  • San Diego, CA (US) (2011 - 2024)
  • Bozeman, MT (US) (2021 - 2024)
  • La Jolla, CA (US) (2024)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Macrocyclic Compounds
Protein Kinases
LIDAR Systems
Chiral Compounds
Calcium Modulators
Diaryl Macrocycles
Polymorphs
Disease Treatment
High Resolution Scanning
Spatial Displacement
47 patents (USPTO):Explore Patents

Title: The Innovative Journey of Evan W. Rogers

Introduction: Evan W. Rogers is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 36 patents, Rogers has dedicated his career to developing innovative solutions for complex medical issues, particularly in the realm of cancer treatment.

Latest Patents: Among his latest contributions, Rogers has disclosed important advancements such as the Diaryl macrocycle polymorph. This invention relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one, which are instrumental in treating diseases like cancer in mammals. Additionally, he has also worked on macrocyclic compounds and their potential to inhibit critical pathways involved in cancer progression, specifically targeting SRC, MET, and CSFR through specialized pharmaceutical compositions.

Career Highlights: Rogers's career has been marked by his tenure at notable companies in the pharmaceutical sector. He has made significant strides while working at Calcimedica, Inc. and Turning Point Therapeutics, Inc. His work in these organizations has continued to propel the advancement of effective treatments for serious health conditions.

Collaborations: Throughout his career, Evan W. Rogers has collaborated with distinguished colleagues, including Jianguo Cao and Zhijun Wang. These partnerships have undoubtedly contributed to the innovation and effectiveness of his patented inventions, leveraging the unique expertise of each collaborator.

Conclusion: Evan W. Rogers represents the spirit of innovation and dedication in the field of pharmaceuticals. With his impactful patents and collaborative efforts, he continues to be a significant figure in the fight against cancer, driving forward the development of new treatments that hold promise for patients and the broader medical community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…